Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ACRS

Aclaris Therapeutics, Inc.

Healthcare | Biotechnology
$4.34 -0.02 (-0.46%) as of 2026-07-14 15:19 UTC
Market Cap$520M
Volume1.09M
EPS (TTM)$-0.53

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a $520M biotechnology company trading at $4.34 (−0.5% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 15:19 UTC.

52-Week Range
Low $1.34High $5.15

What Aclaris Therapeutics, Inc. does

Aclaris Therapeutics develops pharmaceutical products focused on dermatology and related therapeutic areas. The company operates through drug discovery and development platforms, with product candidates including Bosakitug, ATI 9494, ATI 2138, and ATI 052. Aclaris also generates revenue through contract research services and laboratory research activities, supplemented by licensing and collaboration arrangements with partners such as Eli Lilly and Sun Pharmaceutical Industries.

Summarized from Aclaris Therapeutics, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
Key facts
Quote
Price$4.34
Change (1D)-0.02 (-0.46%)
Market cap$520M
Volume1.09M shares
52-week range$1.34 – $5.15
Valuation
EPS (TTM)$-0.53
Price/book5.04×
Returns
52-week return+223.9%
Revenue, margins & earnings
FY2021: net loss $91M on revenue $7M$7MFY2021FY2022: net loss $87M on revenue $30M$30MFY2022FY2023: net loss $88M on revenue $31M$31MFY2023FY2024: net loss $132M on revenue $19M$19MFY2024FY2025: net loss $65M on revenue $8M$8MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-06-08
  • 2026-06-08Mehra AnandM11,580—
  • 2026-06-08Mehra AnandA42,350—
  • 2026-06-08Mehra AnandA10,987—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • BML Capital Management, LLC14,250,000$53.44M0.0%
  • Deep Track Capital, LP9,345,000$35.04M+446.8%
  • BlackRock, Inc.7,407,065$27.78M+8.8%
View QoQ ownership changes →
Company news View all →
No qualifying company news in the archive. Full tape in the platform →
Questions this page answers

What does Aclaris Therapeutics, Inc. do?

Aclaris Therapeutics develops pharmaceutical products focused on dermatology and related therapeutic areas.

What is ACRS's valuation?

ACRS trades at $4.34, as of 2026-07-14.

When did ACRS last file with the SEC?

Aclaris Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 15:19 UTC. This page is also available as JSON at /api/data?ticker=ACRS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACRS and 3,500+ tickers.

Create a free account — keep ACRS
For your agent
GET /api/data?ticker=ACRS

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt